Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study)

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/28896

Title:	Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study)
Authors:	Steingo, Brian Oreja-Guevara, Celia Alroughani, Raed Brassat, David Boyko, Alexey N. McCombe, Pamela VAN WIJMEERSCH, Bart Margolin, David H. Melanson, Maria Daizadeh, Nadia Rodriguez, Claudio E. Vermersch, Patrick
Issue Date:	2018
Publisher:	LIPPINCOTT WILLIAMS & WILKINS
Source:	NEUROLOGY, 90(15) (Art N° P6.376)
Notes:	[Steingo, Brian] Ft Lauderdale Multiple Sclerosis Ctr, Ft Lauderdale, FL USA. [Oreja-Guevara, Celia] Univ Hosp San Carlos, Madrid, Spain. [Alroughani, Raed] Amiri Hosp, Sharq, Kuwait. [Brassat, David] Univ Toulouse, Purpan Hosp, Toulouse, France. [Brassat, David] Univ Toulouse, Mixed Unit Res 1043, Toulouse, France. [Boyko, Alexey N.] Pirogov Russian Natl Res Univ, Moscow, Russia. [Boyko, Alexey N.] Usupov Hosp, Demyelinating Dis Ctr, Moscow, Russia. [McCombe, Pamela] Univ Queensland, Brisbane, Qld, Australia. [Van Wijmeersch, Bart] Hasselt Univ, Rehabil, Hasselt, Belgium. [Van Wijmeersch, Bart] Hasselt Univ, MS Ctr Overpelt, BIOMED, Hasselt, Belgium. [Margolin, David H.; Melanson, Maria; Daizadeh, Nadia; Rodriguez, Claudio E.] Sanofi, Cambridge, MA USA. [Vermersch, Patrick] Univ Lille, Lille, France.
Document URI:	http://hdl.handle.net/1942/28896
ISSN:	0028-3878
e-ISSN:	1526-632X
ISI #:	000453090805102
Rights:	2018, American Academy of Neurology
Category:	M
Type:	Journal Contribution
Appears in Collections:	Research publications

File	Description	Size	Format
Schmidtea mediterranea as an alternative model to predict carcinogenicity via its stem cell responses _ Elsevier Enhanced Reader.pdf Restricted Access	Published version	712.7 kB	Adobe PDF	View/Open Request a copy

20

checked on Sep 7, 2022

6

checked on Sep 7, 2022

Check